One of ten possible COVID-19 vaccine candidates in late-stage testing around the world is showing early signs of success.
Pfizer says preliminary data from trials shows its vaccine may be 90 per cent effective, but there are still multiple questions that need to be answered.
They include how long the vaccine’s effects last and if it also protects older people as well as younger people.
Ottawa has signed a procurement deal with Pfizer for 20-million doses of the vaccine.
(Canadian Press)
